Athira Pharma Inc Cash Flow Conversion Efficiency
Athira Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Athira Pharma Inc (ATHA) has a cash flow conversion efficiency ratio of -0.698x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.40 Million) by net assets ($27.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Athira Pharma Inc (2018–2025)
Cash flow conversion efficiency of Athira Pharma Inc from 2018 to 2025. This chart illustrates how Athira Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Athira Pharma Inc stock price today for real-time trading data and today's change.
Athira Pharma Inc Cash Flow Conversion Ratio Explained
Athira Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Athira Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athira Pharma Inc ranked by their cash flow conversion efficiency. Also see ATHA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trisula Textile Industries Tbk PT
JK:BELL
|
0.074x |
|
Pioneer Power Solutions Inc.
NASDAQ:PPSI
|
-0.033x |
|
Q-Gold Resources Ltd
V:QGR
|
0.311x |
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
0.015x |
|
Worth Peripherals Limited
NSE:WORTH
|
0.067x |
|
DK&D Co.Ltd
KQ:263020
|
0.078x |
|
Central Petroleum Ltd
AU:CTP
|
0.120x |
|
SCD Co. Ltd
KQ:042110
|
0.014x |
Annual Cash Flow Conversion Efficiency for Athira Pharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Athira Pharma Inc from 2018 to 2025. Review ATHA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more